Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review. — CFSMEATLAS
Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.
Du Preez, Stanley, Cabanas, Helene, Staines, Donald et al. · International journal of environmental research and public health · 2021 · DOI
Quick Summary
This review examines a protein called TRPM7 that may play a role in ME/CFS. TRPM7 is an ion channel—a type of gateway that controls how calcium and other minerals move in and out of cells—and it appears to affect the nervous system, immune system, heart, and metabolism. The authors suggest that problems with TRPM7 could help explain some of the complex symptoms seen in ME/CFS, though this is still a developing area of research.
Why It Matters
This review is important because it identifies a specific molecular target (TRPM7) that could help researchers understand the biological mechanisms behind ME/CFS's multi-system symptoms. If TRPM7 dysfunction is confirmed in ME/CFS patients, it could eventually lead to new diagnostic tests or treatment approaches targeting this pathway.
Observed Findings
TRPM7 is increasingly recognized as a key mediator across multiple physiological systems including neurological, immunological, cardiovascular, and metabolic processes.
Dysregulation of TRP melastatin subfamily members and calcium signaling are implicated in the multi-system impairments characteristic of ME/CFS.
TRP ion channels have been identified as playing roles in other neuroimmune disorders such as amyotrophic lateral sclerosis and multiple sclerosis.
Inferred Conclusions
TRPM7 dysfunction represents a plausible candidate mechanism that could explain multi-system pathology in ME/CFS through impaired calcium signaling.
Further targeted research specifically examining TRPM7 expression and function in ME/CFS patients is warranted given the gap in current literature.
Understanding TRPM7's role in neuroimmune disorders may provide insights applicable to ME/CFS pathobiology.
Remaining Questions
Is TRPM7 expression or function actually dysregulated in ME/CFS patients compared to healthy controls?
What specific mechanisms of TRPM7 dysfunction (if present) would link to the cardinal symptoms of ME/CFS such as post-exertional malaise and cognitive impairment?
Could TRPM7-targeted interventions improve clinical outcomes in ME/CFS, and would they address the multi-system nature of the disease?
What This Study Does Not Prove
This review does not establish that TRPM7 dysfunction actually occurs in ME/CFS patients—it is a theoretical proposal based on TRPM7's known roles in other conditions. The paper does not present clinical or laboratory evidence directly measuring TRPM7 activity in ME/CFS cohorts, and correlation between TRPM7 dysregulation and ME/CFS symptoms remains unproven.
How does TRPM7 dysregulation interact with other proposed ME/CFS pathophysiological mechanisms such as viral reactivation or mitochondrial dysfunction?